Olivier Laurent, Ph.D., is a seasoned biotech-pharma R&D leader with deep experience in drug development and bioinformatics.

Dr. Laurent served as Chief Scientific Officer and Head of R&D at Prometheus Biosciences, until the company’s sale to Merck in June 2023. Previously, Dr. Laurent was Chief Scientific Officer at Intrepida Bio, an immuno-oncology company focused on developing novel antibodies for the treatment of fibrotic solid tumors. Before that, he was Chief Scientific Officer at Dauntless Pharmaceuticals, a clinical-stage company developing products in the metabolic and oncology therapeutic areas. Dr. Laurent has 25 years of experience in scientific roles of increasing responsibility, including at Sanofi, Bayer Biotech, Genentech and Pfizer.

While at Pfizer, he was Director of Protein Science and Target Identification and built the company’s peptide bioinformatics group. Dr. Laurent holds a Ph.D. in Cell Biology from the University of Grenoble and is a graduate of the École Normale Supérieure de Lyon in France.